Serina Therapeutics (SER) Non Operating Interest Expenses (2021 - 2026)

Serina Therapeutics has disclosed Non Operating Interest Expenses across 6 years of filings, most recently posting $203000.0 for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses rose 2155.56% year-over-year to $203000.0; the TTM figure through Jun 2026 stood at $416000.0 (up 890.48% YoY), while the FY2025 annual figure was $213000.0, down 59.51% from the prior year.
• Non Operating Interest Expenses came in at $203000.0 for Q2 2026 at Serina Therapeutics, up from $198000.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $978000.0 in Q4 2022 to a low of $6000.0 in Q3 2025.
• Average Non Operating Interest Expenses over 5 years is $296687.5, with a median of $181000.0 recorded in 2023.
• Year-over-year, Non Operating Interest Expenses plunged 97.07% in 2025 and surged 2155.56% in 2026.
• Over 5 years, Non Operating Interest Expenses stood at $978000.0 in 2022, then plunged by 82.0% to $176000.0 in 2023, then tumbled by 90.34% to $17000.0 in 2024, then soared by 1064.71% to $198000.0 in 2025, then increased by 2.53% to $203000.0 in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $203000.0 in Q2 2026, $198000.0 in Q4 2025, and $6000.0 in Q3 2025.